A patient currently taking Adderall XR (mixed amphetamine salts) 30 mg daily wishes to switch to Focalin (dexmethylphenidate). What initial dose of Focalin is most appropriate—5 mg or 15 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Start with 5 mg of Focalin, not 15 mg

When switching from Adderall XR 30 mg to Focalin (dexmethylphenidate), the appropriate starting dose is 5 mg, not 15 mg. This conservative approach is mandated by FDA labeling and supported by established stimulant conversion principles.

Dosing Rationale

The FDA-approved Focalin XR prescribing information explicitly states that for patients currently on methylphenidate, the recommended starting dose is half (1/2) the total daily dose of racemic methylphenidate 1. However, when switching from amphetamine-based medications like Adderall XR to methylphenidate-based medications like Focalin, there is no direct equivalency ratio established in the labeling.

Why 5 mg is the Correct Starting Dose

The FDA label clearly recommends starting with 5 mg for pediatric patients who are not currently taking dexmethylphenidate or racemic methylphenidate, or for patients on stimulants other than methylphenidate 1. Since Adderall XR is an amphetamine-based stimulant (not methylphenidate), this patient falls into the category requiring the standard starting dose of 5 mg.

The American Academy of Child and Adolescent Psychiatry practice parameters support this conservative approach, recommending starting doses of 5 mg for methylphenidate (MPH) and 2.5 mg for dexamphetamine/amphetamine (DEX/AMP) 2. These guidelines emphasize using minimum effective doses to initiate therapy.

Titration Strategy

After starting at 5 mg:

  • Titrate weekly in increments of 5 mg based on symptom response and tolerability 1
  • Monitor for efficacy throughout the day (Focalin XR provides 10-12 hours of coverage) 3, 4
  • The maximum recommended dose is 30 mg daily in pediatric patients and 40 mg in adults 1
  • Assess response using standardized rating scales from parents, teachers, and the patient themselves 2

Critical Safety Considerations

Starting at 15 mg would be inappropriate and potentially dangerous because:

  1. It exceeds the FDA-recommended starting dose by 3-fold
  2. Cross-class stimulant switches (amphetamine to methylphenidate) require conservative dosing due to different mechanisms and receptor profiles
  3. Individual response variability is high—some patients may be highly sensitive to methylphenidate even if tolerating higher amphetamine doses
  4. Side effects like insomnia, decreased appetite, and cardiovascular effects are dose-dependent 5, 6, 3

Monitoring Requirements

Before initiating Focalin:

  • Obtain baseline blood pressure, pulse, height, and weight 2
  • Screen for cardiac disease history and family history of sudden death or arrhythmias 1
  • Evaluate for tics or Tourette's syndrome 1

During titration (weeks 1-4):

  • Weekly contact to assess symptom control and side effects 2
  • Monitor for common adverse effects: insomnia, decreased appetite, headache, agitation 5, 3
  • Obtain feedback from multiple sources (patient, parents, teachers) 2

Common Pitfall to Avoid

Do not attempt direct dose conversion from Adderall XR to Focalin. While some clinicians may try to calculate equivalencies (e.g., assuming 2:1 or 3:1 ratios), these are not evidence-based for cross-class switches. The pharmacokinetic and pharmacodynamic profiles differ substantially between amphetamines and methylphenidate 6, 3. Starting low and titrating based on clinical response is the only safe approach endorsed by FDA labeling and clinical guidelines.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.